Business Wire

CA-JUNIPER-NETWORKS

12.12.2023 08:01:36 CET | Business Wire | Press release

Share
DNA Plc Automates New Data Centers with Juniper Networks® and NEC

Juniper Networks® (NYSE: JNPR), a leader in secure, AI-driven networks, and NEC Corporation (NEC; TSE: 6701), a leading global IT and network transformation services provider, today announced that DNA, part of Telenor Group and one of Finland’s leading mobile and fixed communications service providers, has deployed an intent-based networking data center fabric based on Juniper’s innovative automation software plus high-performance hardware and utilizing NEC’s advanced systems integration expertise. DNA’s new data center infrastructure provides a unified platform for both its business-to-business customer services and internal IT services. Additionally, Juniper Networks™ QFX Series Switches were chosen to power DNA’s Telco Cloud sites across Finland.

The overall objective for DNA’s data center infrastructure refresh is to enable new revenue-generating services whilst delivering operational efficiencies, together leading to enhanced user experiences. By automating the data center network, DNA can eliminate human error, optimize its technical team’s workload to focus on service creation and simplify first-class service delivery at scale. QFX switches enable low latency networking with high reliability and capacity, the key requirements for delivering various services to mobile users who are looking for high-performance network quality.

Juniper Apstra System: Intent-based Networking

  • DNA has selected the Juniper Apstra solution as the data center infrastructure’s foundation: unique, intent-based networking software that simplifies, automates and validates data center design, planning and operations, from Day 0 to Day 2+.
  • Apstra is a turnkey multi-vendor automation solution (both hardware- and OS-agnostic), that provides DNA with a unified, real-time view of millions of data center elements, plus their dynamic performance, relationships and interdependencies.
  • Apstra’s capabilities bring agility and more reliability to DNA’s network design, build and operations. The entire network management operations will be streamlined, and IT teams will be able to focus more on other priorities.
  • With Apstra, DNA can create a set of templates for its data center network built on its desired intent and required business outcomes. Apstra automatically converts this intent into the network configurations and policies necessary to consistently achieve DNA’s defined outcomes.
  • The Apstra-enabled network undergoes continuous, closed-loop assurance and self-validation to ensure compliance with the declared intent from the blueprint.
  • Using the operational, real-time analytics it constantly generates, Apstra is also able to deliver much faster and highly-accurate root-cause analysis of network issues and mitigation data, helping DNA to maximize its data center and services uptime.
  • DNA also deployed Juniper Networks QFX Series Switches across its new data center fabric. The QFX Series complements Apstra in DNA’s network by delivering industry-leading reliability, performance and scalability.
  • NEC is the strategic partner for DNA, providing pre-integration consultancy and validation as well as premium level support for Juniper’s solution, leveraging its expert support team of certified engineers.

Supporting Quotes:

“DNA has always been an innovator, using the best technology available to provide new services and better experiences for our customers. Because Finnish businesses are fully committed to digital transformation, and their expectations of our service reliability and quality are extremely high, we knew that we had to up our game in the data center by deploying state-of-the-art automation and networking technology. By working with Juniper and NEC, DNA is able to deliver those first-class user experiences and maintain our reputation.”

- Pekka Jääskeläinen, Vice President, Core & IP Networks, DNA Plc

“As a long-standing partner to the Telenor Group, NEC is honored to help DNA drive higher efficiency, agility, and availability of its data center network with automated solutions alongside our strategic partner Juniper. Based on our wealth of multi-vendor, multi-domain network systems integration capability and best-of-breed ecosystem, provided by NEC’s Center of Excellence (CoE), we will continue delivering transformative networking solutions and services that overcome increasing business challenges and keep our customers ahead of the curve.”

- Masayuki Kayahara, General Manager, Service Provider Solutions Department, NEC

“Apstra helps to de-risk data center networking significantly but also streamlines the operational overhead, making life much easier for pressured operators. Automation drives down the total cost of ownership in DNA’s data centers and frees up talent, all the while enabling it to open up rich new revenue streams via services which can be taken to market quickly and more reliably.”

- Mansour Karam, Group Vice President Products, Cloud Ready Data Center, Juniper Networks

Additional Resources

Blog: DIY Network Automation – a High-cost Operation for Telecom Data Centers
Research Topic: What is Intent-based Networking?
Infographic: The State of Data Center Network Automation

About Juniper Networks

Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on X (formerly Twitter), LinkedIn and Facebook.

Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.

About NEC Corporation

NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at http://www.nec.com.

LinkedIn: https://www.linkedin.com/company/nec/
YouTube: https://www.youtube.com/user/NECglobalOfficial
Facebook: https://www.facebook.com/nec.global/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231206095386/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release

Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L

2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release

“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release

Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies

FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 13:00:00 CEST | Press release

Partnership includes FIFA tournaments and events from 2031Agreement encompasses both physical and digital collectibles, and for the first time brings the player jersey patch program to international footballPre-match press conferences for the FIFA World Cup Final to take place at Fanatics Fest on Friday, 17 July 2026 In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football tradin

DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 11:21:00 CEST | Press release

Poster presented at ESMO Breast Cancer 2026: Exploring health policy and real-world treatment strategies for early-stage HER2-positive breast cancer across Europe. The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye